Personalis (NASDAQ:PSNL) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Key Points

• Personalis reported an EPS loss of ($0.29), missing the consensus by $0.06 while posting revenue of $15.5M; gross margin compressed to 1.8%, net loss widened to ~$30M, and management guides a full‑year net loss of about $105M with ~$100M cash burn despite ~$233M on the balance sheet.
• The company highlighted strong clinical momentum with 7,800 NeXT Personal tests in Q1 (26% sequential, 258% YoY), >1,000 ordering physicians, a reconfirmed 2026 clinical volume target of 43,000–45,000, and biopharma MRD revenue targets of $20–21M for 2024 (Q1 MRD was $3.1M) with most ramp expected in H2.
• Shares slipped to $5.99 intraday; analysts are mixed but overall rate the stock a "Moderate Buy" with a consensus price target of $11.50 (five Buys, one Hold, one Sell).

Personalis (NASDAQ:PSNL - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06), FiscalAI reports. The firm had revenue of $15.47 million during the quarter, compared to analyst estimates of $14.49 million. Personalis had a negative net margin of 116.69% and a negative return on equity of 39.13%.

Here are the key takeaways from Personalis' conference call:

• Personalis reported strong clinical volume momentum with 7,800 NeXT Personal tests in Q1 (26% sequential, 258% YoY), surpassed >1,000 ordering physicians in the quarter, and reconfirmed a 2026 clinical volume target of 43,000–45,000 tests.
• Q1 revenue was $15.5M (down ~25% YoY) and gross margin compressed to 1.8% due to unreimbursed scaling; net loss widened to $30M and full-year net loss is guided to about $105M with ~$100M expected cash usage despite a $233M cash balance.
• Reimbursement and clinical evidence progress: Medicare coverage for breast and lung surveillance is live, MolDX submissions are pending for neoadjuvant breast and pan‑cancer IO, and presented data (NEOPRISM‑CRC, DARWIN‑2, 10k real‑world cohort) highlighted high negative predictive value and the value of ultrasensitivity.
• Biopharma MRD momentum and backlog are growing: Q1 biopharma MRD revenue was $3.1M with management targeting $20M–$21M for the full year, expecting most MRD revenue to ramp in H2 as several large trials commence.

Personalis Stock Performance

Personalis stock traded down $0.08 during midday trading on Thursday, reaching $5.99. The company's stock had a trading volume of 1,509,398 shares, compared to its average volume of 2,054,222. Personalis has a fifty-two week low of $3.84 and a fifty-two week high of $11.50. The stock's 50 day simple moving average is $6.93 and its 200 day simple moving average is $8.23. The firm has a market capitalization of $627.03 million, a PE ratio of -6.58 and a beta of 1.96.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Personalis in a report on Tuesday, April 21st. BTIG Research increased their price target on Personalis from $12.00 to $13.00 and gave the stock a "buy" rating in a report on Wednesday, February 11th. Needham & Company LLC increased their price target on Personalis from $10.00 to $12.00 and gave the stock a "buy" rating in a report on Friday, February 27th. Guggenheim increased their price target on Personalis from $12.00 to $13.00 and gave the stock a "buy" rating in a report on Monday, January 26th. Finally, Morgan Stanley decreased their price target on Personalis from $11.00 to $10.00 and set an "equal weight" rating for the company in a report on Thursday, March 5th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $11.50.

Institutional Investors Weigh In On Personalis

Hedge funds and other institutional investors have recently bought and sold shares of the business. Rhumbline Advisers lifted its holdings in Personalis by 2,037.2% in the second quarter. Rhumbline Advisers now owns 79,268 shares of the company's stock valued at $520,000 after acquiring an additional 75,559 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Personalis in the second quarter valued at $459,000. Verition Fund Management LLC acquired a new stake in Personalis in the fourth quarter valued at $412,000. Polen Capital Management LLC acquired a new stake in Personalis in the fourth quarter valued at $404,000. Finally, Man Group plc acquired a new stake in Personalis in the second quarter valued at $324,000. Institutional investors and hedge funds own 61.91% of the company's stock.

About Personalis

Personalis, Inc NASDAQ: PSNL is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company's core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.